

James D Perkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5714668/publications.pdf>

Version: 2024-02-01

309
papers

6,369
citations

76196

40
h-index

76769

74
g-index

310
all docs

310
docs citations

310
times ranked

5751
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute Graft-versus-Host Disease After Orthotopic Liver Transplantation: Predicting This Rare Complication Using Machine Learning. <i>Liver Transplantation</i> , 2022, 28, 407-421.	1.3	7
2	Building a Utility-based Liver Allocation Model in Preparation for Continuous Distribution. <i>Transplantation Direct</i> , 2022, 8, e1282.	0.8	1
3	Optimizing Risk Assessment In Simultaneous Liver and Kidney Transplant: Donor and Recipient Factors Associated With Improved Outcome. <i>Transplantation Proceedings</i> , 2022, 54, 715-715.	0.3	0
4	The impact of the COVID-19 pandemic on medical student education: Implementation and outcome of a virtual general surgery curriculum. <i>American Journal of Surgery</i> , 2022, , .	0.9	6
5	Exploring the Influence of Gender on Surgical Clerkship Grades and Test Scores: A Single Institution, Multisite Comparison. <i>Journal of Surgical Education</i> , 2022, 79, 1132-1139.	1.2	2
6	Do funding sources influence long-term patient survival in pediatric liver transplantation?. <i>Pediatric Transplantation</i> , 2021, 25, e13887.	0.5	6
7	Machine Perfusion Decreases Delayed Graft Function in Donor Grafts With High Kidney Donor Profile Index. <i>Experimental and Clinical Transplantation</i> , 2021, 19, 8-13.	0.2	4
8	Effect of Donor Transaminase Levels on Graft Survival Following Liver Transplant: An Analysis of the Organ Procurement and Transplantation Network Database. <i>Experimental and Clinical Transplantation</i> , 2021, 19, 250-258.	0.2	1
9	Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients. <i>Liver Transplantation</i> , 2021, 27, 1302-1311.	1.3	8
10	Donor-Recipient BSA Matching Is Prognostically Significant in Solitary and En Bloc Kidney Transplantation From Pediatric Circulatory Death Donors. <i>Transplantation Direct</i> , 2021, 7, e733.	0.8	0
11	Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients. <i>Transplantation Direct</i> , 2021, 7, e637.	0.8	0
12	New Evidence Supporting Increased Use of Split Liver Transplantation. <i>Transplantation</i> , 2020, 104, 299-307.	0.5	19
13	Living vs deceased donor liver transplantation in cholestatic liver disease: An analysis of the OPTN database. <i>Clinical Transplantation</i> , 2020, 34, e14031.	0.8	5
14	End-of-Life Care among US Adults with ESKD Who Were Waitlisted or Received a Kidney Transplant, 2005-2014. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2424-2433.	3.0	10
15	The impact of public health service increased risk donors in pediatric liver transplantation. <i>Pediatric Transplantation</i> , 2020, 24, e13712.	0.5	3
16	Livers From Pediatric Donation After Circulatory Death Donors Represent a Viable and Underutilized Source of Allograft. <i>Liver Transplantation</i> , 2020, 26, 1138-1153.	1.3	6
17	Contemporary patterns in kidney graft survival from donors after circulatory death in the United States. <i>PLoS ONE</i> , 2020, 15, e0233610.	1.1	7
18	Expanding Blood Type A2 to B Liver Transplantation: An Alternative for High Model for End-Stage Liver Disease Score Patients. <i>Liver Transplantation</i> , 2020, 26, 1532-1533.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Adults transplanted as children as retransplant candidates: Analysis of outcomes support optimism in a population mislabeled as high risk. <i>Clinical Transplantation</i> , 2020, 34, e13880.	0.8	1
20	Title is missing!. , 2020, 15, e0233610.		0
21	Title is missing!. , 2020, 15, e0233610.		0
22	Title is missing!. , 2020, 15, e0233610.		0
23	Title is missing!. , 2020, 15, e0233610.		0
24	Title is missing!. , 2020, 15, e0233610.		0
25	Title is missing!. , 2020, 15, e0233610.		0
26	Title is missing!. , 2020, 15, e0233610.		0
27	Title is missing!. , 2020, 15, e0233610.		0
28	Size mismatch in deceased donor liver transplantation and its impact on graft survival. <i>Clinical Transplantation</i> , 2019, 33, e13662.	0.8	26
29	Three-year follow-up of aviremic hepatitis Câ€“positive kidneys. <i>American Journal of Transplantation</i> , 2019, 19, 3212-3213.	2.6	4
30	Burden of excess mortality after implementation of the new kidney allocation system may be borne disproportionately by middle-aged recipients. <i>PLoS ONE</i> , 2019, 14, e0210589.	1.1	5
31	Listing practices and graft utilization of hepatitis Câ€“positive deceased donors in liver and kidney transplant. <i>Surgery</i> , 2019, 166, 102-108.	1.0	9
32	Impact of Insurance Status on Outcomes of Children Undergoing Liver Transplantation. <i>Journal of the American College of Surgeons</i> , 2019, 229, e17.	0.2	0
33	Living liver donation improves patient and graft survival in the pediatric population. <i>Pediatric Transplantation</i> , 2019, 23, e13318.	0.5	20
34	Living Donation Versus Donation After Circulatory Death Liver Transplantation for Low Model for Endâ€“Stage Liver Disease Recipients. <i>Liver Transplantation</i> , 2019, 25, 580-587.	1.3	11
35	Resection margin distance in extrahepatic cholangiocarcinoma: How much is enough?. <i>Journal of Clinical Oncology</i> , 2019, 37, 455-455.	0.8	0
36	Unintended Consequences in Use of Increased Risk Donor Kidneys in the New Kidney Allocation Era. <i>Transplantation Proceedings</i> , 2018, 50, 14-19.	0.3	3

#	ARTICLE	IF	CITATIONS
37	Utilization of Standard Criteria Donor and Expanded Criteria Donor Kidneys After Kidney Allocation System Implementation. <i>Annals of Transplantation</i> , 2018, 23, 691-703.	0.5	4
38	Can we mitigate the effects of simultaneous liver-kidney transplantation through increased utilization of HCV-positive donors?. <i>American Journal of Transplantation</i> , 2018, 18, 2604-2605.	2.6	1
39	NKT Cells in the Liver are Important for Peripheral Tolerance Induction. <i>Transplantation</i> , 2018, 102, S694.	0.5	1
40	Willingness to Consider Increased-Risk Donors: A Single-Center Experience in Kidney Transplantation. <i>Annals of Transplantation</i> , 2018, 23, 387-392.	0.5	8
41	Clinical Impact and Risk Factors of Portal Vein Thrombosis for Patients on Wait List for Liver Transplant. <i>Experimental and Clinical Transplantation</i> , 2018, 16, 166-171.	0.2	11
42	Recent trends in liver transplantation for alcoholic liver disease in the United States. <i>World Journal of Hepatology</i> , 2017, 9, 1315-1321.	0.8	22
43	Kidney Biopsies May Help Predict Renal Function After Liver Transplantation. <i>Transplantation</i> , 2016, 100, 2122-2128.	0.5	30
44	Circulating Epithelial Cells in Patients with Pancreatic Lesions: Clinical and Pathologic Findings. <i>Journal of the American College of Surgeons</i> , 2015, 221, 699-707.	0.2	64
45	Outcomes after combined liver-kidney transplant vs. kidney transplant followed by liver transplant. <i>Clinical Transplantation</i> , 2015, 29, 60-66.	0.8	3
46	Advancing the High Throughput Identification of Liver Fibrosis Protein Signatures Using Multiplexed Ion Mobility Spectrometry. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1119-1127.	2.5	51
47	D-MELD risk capping improves post-transplant and overall mortality under markov microsimulation. <i>World Journal of Transplantation</i> , 2014, 4, 206.	0.6	2
48	PD-L1 Signal on Liver Dendritic Cells Is Critical for Foxp3+CD4+CD25+ Treg and Liver Tolerance Induction in Mice. <i>Transplantation Proceedings</i> , 2013, 45, 1853-1855.	0.3	36
49	Looking Beyond the Test. <i>American Journal of the Medical Sciences</i> , 2013, 346, 234-235.	0.4	0
50	The HALOS-ND model: a step in the journey of predicting hospital length of stay after liver transplantation. <i>Clinical Transplantation</i> , 2013, 27, 809-822.	0.8	6
51	Molecular Signatures of Recurrent Hepatocellular Carcinoma Secondary to Hepatitis C Virus following Liver Transplantation. <i>Journal of Transplantation</i> , 2013, 2013, 1-14.	0.3	9
52	Hepatic artery thrombosis and liver malignancy in pediatric liver transplantation. <i>Journal of Pediatric Surgery</i> , 2012, 47, 1255-1260.	0.8	21
53	Clinical factors predicting readmission after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2012, 18, 1037-1045.	1.3	53
54	Treatment of an elderly patient with hepatocellular carcinoma: Counseling from the patient's point of view. <i>Liver Transplantation</i> , 2012, 18, 391-394.	1.3	3

#	ARTICLE	IF	CITATIONS
55	Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation. <i>Hepatology</i> , 2012, 56, 28-38.	3.6	39
56	Risk stratification of kidneys from donation after cardiac death donors and the utility of machine perfusion. <i>Clinical Transplantation</i> , 2011, 25, E530-40.	0.8	29
57	Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation. <i>Virology</i> , 2010, 402, 248-255.	1.1	13
58	The biopsied donor liver: Incorporating macrosteatosis into high-risk donor assessment. <i>Liver Transplantation</i> , 2010, 16, 874-884.	1.3	299
59	Impact of obesity on children undergoing liver transplantation. <i>Liver Transplantation</i> , 2010, 16, 1296-1302.	1.3	23
60	Intraoperative portal vein blood flow predicts allograft and patient survival following liver transplantation. <i>Hpb</i> , 2010, 12, 166-173.	0.1	49
61	Identifying the futile pediatric liver re-transplant in the PELD era. <i>Pediatric Transplantation</i> , 2010, 14, 1019-1029.	0.5	14
62	Outcomes in Children After Intestinal Transplant. <i>Pediatrics</i> , 2010, 125, e550-e558.	1.0	62
63	Use of an automated clinical management system improves outpatient immunosuppressive care following liver transplantation. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2010, 17, 396-402.	2.2	10
64	Outcomes in children with intestinal failure following listing for intestinal transplant. <i>Journal of Pediatric Surgery</i> , 2010, 45, 100-107.	0.8	14
65	Uterine Leiomyoma in an Adolescent Female. <i>Journal of the National Medical Association</i> , 2009, 101, 611-613.	0.6	11
66	Combination of Peritubular C4d and Transplant Glomerulopathy Predicts Late Renal Allograft Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2260-2268.	3.0	66
67	Balloon dilation only versus balloon dilation plus stenting for posttransplantation biliary strictures. <i>Liver Transplantation</i> , 2009, 15, 106-110.	1.3	5
68	Should liver transplantation in patients with model for end-stage liver disease scores ≥ 14 be avoided? A decision analysis approach. <i>Liver Transplantation</i> , 2009, 15, 242-254.	1.3	25
69	Systematic review on preventing bacterial sepsis and wound complications in liver transplant patients. <i>Liver Transplantation</i> , 2009, 15, 255-259.	1.3	0
70	Timing of liver transplantation following transjugular intrahepatic portosystemic shunt in patients with Budd-Chiari syndrome. <i>Liver Transplantation</i> , 2009, 15, 341-346.	1.3	1
71	The impact of consecutive operations on survival after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 907-914.	1.3	12
72	Biodegradable Bile Duct Stents: Use in Liver Transplantation?. <i>Liver Transplantation</i> , 2009, 15, 440-445.	1.3	1

#	ARTICLE	IF	CITATIONS
73	The extent of hepatectomy depends on the preoperative model for end-stage liver disease score. Liver Transplantation, 2009, 15, 551-555.	1.3	0
74	Safety of invasive procedures in end-stage liver disease patients. Liver Transplantation, 2009, 15, 656-661.	1.3	0
75	Use of transjugular intrahepatic portosystemic shunts after liver transplantation. Liver Transplantation, 2009, 15, 810-815.	1.3	0
76	Another formula to determine the prognosis of patients with acute liver failure. Liver Transplantation, 2009, 15, 986-991.	1.3	15
77	A new clinical method to measure hepatic microcirculation. Liver Transplantation, 2009, 15, 1149-1153.	1.3	0
78	Infrahepatic cavocavostomy: Expanding the armamentarium for the liver transplant surgeon. Liver Transplantation, 2009, 15, 1365-1369.	1.3	2
79	Reversibility of posttransplantation diabetes mellitus following liver transplantation. Liver Transplantation, 2009, 15, 1631-1636.	1.3	0
80	Risk Factors for Developing Ischemic-Type Biliary Lesions After Liver Transplantation. Liver Transplantation, 2009, 15, 1882-1887.	1.3	4
81	Pretransplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation. Clinical Transplantation, 2009, 23, 874-881.	0.8	30
82	Liver transplantation at the extremes of the body mass index. Liver Transplantation, 2009, 15, 968-977.	1.3	168
83	Cost of liver transplantation. Liver Transplantation, 2009, 15, 342-3.	1.3	0
84	Immunosuppressive strategies to prevent hepatitis C recurrence. Liver Transplantation, 2009, 15, 343-5.	1.3	0
85	Longer waiting times for obese liver transplant patients. Liver Transplantation, 2009, 15, 345-6.	1.3	0
86	Methicillin-resistant staphylococcus aureus in liver programs. Liver Transplantation, 2009, 15, 441-2.	1.3	0
87	Another comparison between University of Wisconsin solution and histidine-tryptophan-ketoglutarate solution for liver preservation. Liver Transplantation, 2009, 15, 443-4.	1.3	0
88	The various functions of CD4+ Foxp3+ regulatory T cells in liver disease and transplantation. Liver Transplantation, 2009, 15, 444-5.	1.3	0
89	Acute physiology and chronic health evaluation scores for predicting outcomes in urgent liver transplants. Liver Transplantation, 2009, 15, 657-8.	1.3	0
90	The evolving story of new food allergies following liver transplantation. Liver Transplantation, 2009, 15, 658-9.	1.3	0

#	ARTICLE	IF	CITATIONS
91	Institution of a standard procedure to prevent hepatic artery thrombosis. Liver Transplantation, 2009, 15, 659-61.	1.3	0
92	Does correcting hyponatremia improve liver transplant outcomes?. Liver Transplantation, 2009, 15, 811-3.	1.3	0
93	Is there any benefit to laparoscopic liver resection for hepatocellular carcinoma if a salvage liver transplant is needed later?. Liver Transplantation, 2009, 15, 813-4.	1.3	1
94	Follow-up on platelet transfusion causing decreased postoperative survival after liver transplantation. Liver Transplantation, 2009, 15, 814-5.	1.3	0
95	Should split-liver transplantation be avoided in critically ill adult recipients?. Liver Transplantation, 2009, 15, 1150-1.	1.3	0
96	Control of intraoperative glucose levels during liver transplantation to lower the incidence of surgical site infections. Liver Transplantation, 2009, 15, 1151-2.	1.3	0
97	Increasing CD4+FOXP3+ regulatory T cells in human liver allografts. Liver Transplantation, 2009, 15, 1152-3.	1.3	0
98	Defatting the fatty liver with normothermic perfusion of the liver allograft. Liver Transplantation, 2009, 15, 1366-7.	1.3	2
99	Is survival after liver transplantation for hepatocellular carcinoma influenced by the etiology of the liver disease?. Liver Transplantation, 2009, 15, 1367-8.	1.3	0
100	Should intraportal insulin administration become routine in clinical transplant care?. Liver Transplantation, 2009, 15, 1368-9.	1.3	0
101	Some liver transplant patients have reduced neutrophil activation: so what?. Liver Transplantation, 2009, 15, 1632-3.	1.3	0
102	What price do we pay for reconstruction of the hepatic arteries of deceased donors?. Liver Transplantation, 2009, 15, 1633-5.	1.3	0
103	Continuing search for the test to measure liver function capacity. Liver Transplantation, 2009, 15, 1635-6.	1.3	0
104	Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors. Liver Transplantation, 2008, 14, 604-610.	1.3	207
105	Another patient with an umbilical hernia and massive ascites: What to do?. Liver Transplantation, 2008, 14, 110-114.	1.3	3
106	Hyperkalemia and liver transplantation. Liver Transplantation, 2008, 14, 252-256.	1.3	6
107	Preemptive treatment of fungal infection: has its time arrived in liver transplantation?. Liver Transplantation, 2008, 14, 380-384.	1.3	0
108	Treatment of Small-For-Size Syndrome. Liver Transplantation, 2008, 14, 571-575.	1.3	4

#	ARTICLE	IF	CITATIONS
109	Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: Implications for surveillance studies and new adjuvant therapies. <i>Liver Transplantation</i> , 2008, 14, 956-965.	1.3	56
110	Platelet transfusions have a negative impact on liver transplant survival. <i>Liver Transplantation</i> , 2008, 14, 701-705.	1.3	2
111	When is a liver transplant futile?. <i>Liver Transplantation</i> , 2008, 14, 899-904.	1.3	2
112	Cancer stem cells in the blood: Possible therapeutic implications. <i>Liver Transplantation</i> , 2008, 14, 1060-1064.	1.3	1
113	Alternative source of inflow to the donor hepatic arteries. <i>Liver Transplantation</i> , 2008, 14, 1216-1220.	1.3	1
114	Biliary tract complications: The most common postoperative complication in living liver donors. <i>Liver Transplantation</i> , 2008, 14, 1372-1377.	1.3	1
115	Patient Transplant Survival Not Influenced by Type of Liver Graft. <i>Liver Transplantation</i> , 2008, 14, 1533-1537.	1.3	1
116	Accuracy of detecting hepatocellular carcinomas before liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 1675-1679.	1.3	0
117	Continuing Success with Down-Staging of Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2008, 14, 1810-1815.	1.3	1
118	Liver Transplantation for Hepatocellular Carcinoma: Impact of the MELD Allocation System and Predictors of Survival. <i>Gastroenterology</i> , 2008, 134, 1342-1351.	0.6	240
119	Investigation of Putative Multisubtype Hepatitis C Virus Infections In Vivo by Heteroduplex Mobility Analysis of Core/Envelope Subgenomes. <i>Journal of Virology</i> , 2008, 82, 7524-7532.	1.5	15
120	Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 943-953.	0.7	52
121	PD-L1/PD-1 Signal Deficiency Promotes Allogeneic Immune Responses and Accelerates Heart Allograft Rejection. <i>Transplantation</i> , 2008, 86, 836-844.	0.5	29
122	Contaminated salvaged blood in liver transplant patients. <i>Liver Transplantation</i> , 2008, 14, 111-2.	1.3	0
123	Avascular necrosis: a problem for liver transplant patients?. <i>Liver Transplantation</i> , 2008, 14, 112-3.	1.3	0
124	Liver Allocation in the United Kingdom. <i>Liver Transplantation</i> , 2008, 14, 113-4.	1.3	0
125	<i>Clostridium difficile</i> colitis associated with other complications following liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 253-4.	1.3	1
126	Models for predicting graft and patient survival and hepatitis C virus recurrence after liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 254-55.	1.3	0

#	ARTICLE	IF	CITATIONS
127	Estimating life-years: enter the argument to use split livers versus whole livers. Liver Transplantation, 2008, 14, 255-56.	1.3	0
128	The etiology of portal vein thrombosis in patients with hepatocellular carcinoma requires a vigilant diagnostic approach. Liver Transplantation, 2008, 14, 572-3.	1.3	0
129	Different liver transplant survival rates across the pond. Liver Transplantation, 2008, 14, 573-4.	1.3	0
130	Massive pulmonary embolism during liver transplantation. Liver Transplantation, 2008, 14, 575.	1.3	0
131	Have you seen a liver transplant patient with a cytomegalovirus-associated ophthalmologic complication?. Liver Transplantation, 2008, 14, 702-3.	1.3	0
132	How do you perform your hepatic arterial anastomosis? Traditional or straight?. Liver Transplantation, 2008, 14, 703-4.	1.3	0
133	The cost of liver transplant complications. Liver Transplantation, 2008, 14, 704-5.	1.3	0
134	Computerized care for transplant patients computerized alerts improve outpatient laboratory monitoring of transplant patients. Liver Transplantation, 2008, 14, 1217-8.	1.3	0
135	Another chapter involving plasmacytoid dendritic cells and immunologic tolerance. Liver Transplantation, 2008, 14, 1218-9.	1.3	0
136	Sinusoidal obstructive syndrome: a rare and stressful indication for liver transplantation. Liver Transplantation, 2008, 14, 1219-20.	1.3	0
137	Evolution and standardization of microchimerism detection techniques: potential new discoveries?. Liver Transplantation, 2008, 14, 1373-4.	1.3	0
138	Another cardiac output device for study during liver transplantation. Liver Transplantation, 2008, 14, 1374-5.	1.3	0
139	Surgical Dogma challenged in liver transplantation for hepatocellular carcinoma. Liver Transplantation, 2008, 14, 1376-7.	1.3	0
140	Chronic complex bile duct injury: proceed to liver transplantation or another corrective operation. Liver Transplantation, 2008, 14, 1534-5.	1.3	0
141	Molecular markers for predicting hepatocellular carcinoma recurrence following liver transplantation. Liver Transplantation, 2008, 14, 1535-6.	1.3	0
142	Colonoscopic surveillance following liver transplantation. Liver Transplantation, 2008, 14, 1536-7.	1.3	0
143	Predicting cost in liver transplantation. Liver Transplantation, 2008, 14, 1676-7.	1.3	0
144	How old is too old to receive a living donor liver?. Liver Transplantation, 2008, 14, 1677-8.	1.3	0

#	ARTICLE	IF	CITATIONS
145	The methods used to diagnose invasive aspergillosis in the liver transplant recipient continue to evolve. Liver Transplantation, 2008, 14, 1678-9.	1.3	0
146	What prophylaxis schedule should we use for Pneumocystis jiroveci pneumonia in our liver transplant recipients?. Liver Transplantation, 2008, 14, 1811-2.	1.3	0
147	Immunosuppressive therapy and inflammatory bowel disease after transplantation. Liver Transplantation, 2008, 14, 1812-3.	1.3	1
148	Incidence of portal vein complications following liver transplantation. Liver Transplantation, 2008, 14, 1813-5.	1.3	2
149	Left ventricular dysfunction: A hidden risk in patients undergoing liver transplantation. Liver Transplantation, 2007, 13, 165-169.	1.3	3
150	Incisional hernia repair after liver transplantation: A second editorial look. Liver Transplantation, 2007, 13, 302-305.	1.3	7
151	Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients. Liver Transplantation, 2007, 13, 516-522.	1.3	54
152	Screening for portopulmonary hypertension. Liver Transplantation, 2007, 13, 463-467.	1.3	6
153	Reply to: Which is the best timing of bile duct division in living liver donor surgery?. Liver Transplantation, 2007, 13, 1206-1206.	1.3	0
154	Optical coherence tomography: Expanding use in the bile duct. Liver Transplantation, 2007, 13, 765-768.	1.3	1
155	Thrombolysis for early hepatic artery thrombosis: Definitive therapy or diagnostic aid?. Liver Transplantation, 2007, 13, 927-931.	1.3	5
156	Reply to: Selecting patients with hepatocellular carcinoma for transplantation. Liver Transplantation, 2007, 13, 1204-1204.	1.3	0
157	Recurrent hepatocellular carcinoma is a problem we need to tackle. Liver Transplantation, 2007, 13, 1057-1061.	1.3	7
158	Reply: Distinguishing between hepatic portal vein gas and pneumo(aero)bilia. Liver Transplantation, 2007, 13, 1477-1477.	1.3	2
159	Who is at risk for developing cytomegalovirus (CMV) infection following liver transplantation?. Liver Transplantation, 2007, 13, 1195-1198.	1.3	2
160	Incisional hernia following liver transplantation: Today's incidence and causes of this pesky problem. Liver Transplantation, 2007, 13, 1339-1342.	1.3	6
161	Rh blood group and liver transplantation. Liver Transplantation, 2007, 13, 1463-1467.	1.3	1
162	Reply: Geographic disparities and deceased donor liver transplantation within a single UNOS region. Liver Transplantation, 2007, 13, 1761-1761.	1.3	2

#	ARTICLE	IF	CITATIONS
163	Seeding risk following percutaneous approach to hepatocellular carcinoma. Liver Transplantation, 2007, 13, 1603-1607.	1.3	32
164	Venous outflow obstruction in liver transplantation is associated with the anastomotic technique. Liver Transplantation, 2007, 13, 1751-1755.	1.3	0
165	Influence of the liver graft on post-transplantation hepatitis C antiviral therapy. Liver Transplantation, 2007, 13, 166-7.	1.3	0
166	The expanding role of nanoparticles in the treatment of liver disease. Liver Transplantation, 2007, 13, 167-8.	1.3	1
167	"Tiny bubbles in our livers". Liver Transplantation, 2007, 13, 168-9.	1.3	0
168	Help needed for pretransplant depression. Liver Transplantation, 2007, 13, 303.	1.3	0
169	C4d deposits as a possible marker for acute cellular liver rejection. Liver Transplantation, 2007, 13, 303-4.	1.3	1
170	Use of Aspergillus galactomannan enzyme-linked immunosorbent assay (ELISA) in liver transplant patients. Liver Transplantation, 2007, 13, 304-5.	1.3	3
171	Recurrence of hepatocellular carcinoma: it's in the genes?. Liver Transplantation, 2007, 13, 464-5.	1.3	0
172	Are we reporting the same thing?. Liver Transplantation, 2007, 13, 465-6.	1.3	14
173	The evolution of caval implantation in liver transplantation. Liver Transplantation, 2007, 13, 466-7.	1.3	0
174	A new culture system to study hepatitis C virus. Liver Transplantation, 2007, 13, 765-6.	1.3	0
175	Hepatocellular resectability depends on the "Eye of the Beholder". Liver Transplantation, 2007, 13, 766-7.	1.3	0
176	Techniques to ensure adequate portal flow in the presence of splenorenal shunts. Liver Transplantation, 2007, 13, 767-8.	1.3	12
177	Influence of obesity with concurrent diseases on liver transplant survival. Liver Transplantation, 2007, 13, 928-9.	1.3	3
178	Liver volume is critical: how best to gauge size. Liver Transplantation, 2007, 13, 929-30.	1.3	0
179	Irradiation of blood products: do we need to do that?. Liver Transplantation, 2007, 13, 930-1.	1.3	0
180	Expanding role of minimally invasive aspiration biopsy after liver transplantation. Liver Transplantation, 2007, 13, 1198.	1.3	0

#	ARTICLE	IF	CITATIONS
181	Access to liver transplantation: still a controversial issue. <i>Liver Transplantation</i> , 2007, 13, 1340-1.	1.3	0
182	Lipid blood levels and neurological events in liver transplant patients. <i>Liver Transplantation</i> , 2007, 13, 1341-2.	1.3	0
183	Evasive nature of the hepatitis C virus. <i>Liver Transplantation</i> , 2007, 13, 1342.	1.3	0
184	Transplanted patients with combined hepatocellular-cholangiocarcinoma: now what?. <i>Liver Transplantation</i> , 2007, 13, 1465-6.	1.3	3
185	Exosomes?. <i>Liver Transplantation</i> , 2007, 13, 1466-7.	1.3	0
186	Early Development of nanoprobes for diagnostic imaging. <i>Liver Transplantation</i> , 2007, 13, 1604.	1.3	0
187	Evolving treatment of biliary strictures following liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 1605-7.	1.3	4
188	Quality of life after liver transplantation for acute hepatic failure. <i>Liver Transplantation</i> , 2007, 13, 1604-5.	1.3	0
189	Profound thrombocytopenia immediately following liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 1753-4.	1.3	0
190	A simple treatment to prevent ischemia-reperfusion injury of the liver. <i>Liver Transplantation</i> , 2007, 13, 1755.	1.3	0
191	Productive Replication of Hepatitis C Virus in Perihepatic Lymph Nodes In Vivo: Implications of HCV Lymphotropism. <i>Gastroenterology</i> , 2006, 130, 1107-1116.	0.6	141
192	Enhancement of NKT Cells and Increase in Regulatory T Cells Results in Improved Allograft Survival. <i>Journal of Surgical Research</i> , 2006, 134, 10-21.	0.8	7
193	The Role of Foxp3+ Regulatory T Cells in Liver Transplant Tolerance. <i>Transplantation Proceedings</i> , 2006, 38, 3205-3206.	0.3	54
194	Anti-CD25 mAb Administration Prevents Spontaneous Liver Transplant Tolerance. <i>Transplantation Proceedings</i> , 2006, 38, 3207-3208.	0.3	41
195	Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis. <i>Transplantation</i> , 2006, 81, 1645-1652.	0.5	217
196	Liver transplantation worldwide. <i>Liver Transplantation</i> , 2006, 12, 159-162.	1.3	8
197	Indications for chronic albumin infusion. <i>Liver Transplantation</i> , 2006, 12, 320-323.	1.3	0
198	Metabolic syndrome: A new view of some familiar transplant risks. <i>Liver Transplantation</i> , 2006, 12, 485-489.	1.3	4

#	ARTICLE	IF	CITATIONS
199	Acetaminophen sets records in the United States: Number 1 analgesic and number 1 cause of acute liver failure. <i>Liver Transplantation</i> , 2006, 12, 682-686.	1.3	15
200	Immediate tracheal extubation following liver transplantation: Fast track in liver transplantation: 5 years' experience. Biancofiore G, Bindi ML, Romanelli AM, Boldrini A, Bisà M, Esposito M, Urbani L, Catalano G, Mosca F, Filipponi F. <i>Eur J Anaesthesiol</i> 2005;22:584-590. <i>Liver Transplantation</i> , 2006, 12, 883-887.	1.3	7
201	Saying "eyes" to obese living liver donors: Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Nakamura M, Morizono S, Soejima Y, Yoshizumi T, Aishima S, Takasugi S, et al. <i>Transplantation</i> 2005;80:608-612. <i>Liver Transplantation</i> , 2006, 12, 1012-1016.	1.3	29
202	Aprotinin: Effective, but risky?. <i>Liver Transplantation</i> , 2006, 12, 1293-1297.	1.3	4
203	The amazing regenerative powers of the liver. <i>Liver Transplantation</i> , 2006, 12, 1431-1434.	1.3	2
204	The influence of CTLA-4 gene polymorphisms on liver transplant outcomes. <i>Liver Transplantation</i> , 2006, 12, 1552-1556.	1.3	4
205	Acute liver failure in children: They really are not just small adults: Acute liver failure in children: The first 348 patients in the Pediatric Acute Liver Failure Study Group. Squires RH Jr, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz, et al. <i>J Pediatr</i> 2006;148:652-658. <i>Liver Transplantation</i> , 2006, 12, 1715-1719.	1.3	9
206	Liver sinusoidal endothelial cells: Their unique role in immune tolerance. <i>Liver Transplantation</i> , 2006, 12, 1900-1903.	1.3	1
207	Hepatic venous outflow obstruction after piggyback orthotopic liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 159-60.	1.3	2
208	Adrenal failure in liver transplant patients: does steroid-free immunosuppression place recipients at risk for an adrenal crisis?. <i>Liver Transplantation</i> , 2006, 12, 160-2.	1.3	3
209	The hemodynamics of cirrhosis and the development of hepatorenal syndrome. <i>Liver Transplantation</i> , 2006, 12, 162.	1.3	0
210	Percutaneous transhepatic balloon dilation for portal venous stenosis. <i>Liver Transplantation</i> , 2006, 12, 321-2.	1.3	1
211	Hemochromatosis and liver transplant survival. <i>Liver Transplantation</i> , 2006, 12, 322.	1.3	0
212	Infection by proxy: the role of chimeric mice in HBV and HCV research. <i>Liver Transplantation</i> , 2006, 12, 323.	1.3	0
213	Quality takes center stage in transplantation. <i>Liver Transplantation</i> , 2006, 12, 486-7.	1.3	0
214	Increasing the liver donor pool through donation after cardiac death. <i>Liver Transplantation</i> , 2006, 12, 487-8.	1.3	0
215	Predicting posttransplantation infection risk with gene polymorphisms. <i>Liver Transplantation</i> , 2006, 12, 488-9.	1.3	0
216	Old foe learns new tricks. <i>Liver Transplantation</i> , 2006, 12, 683.	1.3	0

#	ARTICLE	IF	CITATIONS
217	Genetics or environment?. Liver Transplantation, 2006, 12, 684.	1.3	0
218	Alternative approaches to evaluating cirrhotic patients for laparoscopic cholecystectomy. Liver Transplantation, 2006, 12, 684-6.	1.3	0
219	Polypropylene mesh for hernia repair following transplantation. Liver Transplantation, 2006, 12, 884-5.	1.3	0
220	To biopsy or not to biopsy?. Liver Transplantation, 2006, 12, 885-6.	1.3	0
221	Treatment strategies for posttransplant lymphoproliferative disorder. Liver Transplantation, 2006, 12, 1013-4.	1.3	0
222	Intensive insulin therapy improves survival in critically ill patients: how does it work?. Liver Transplantation, 2006, 12, 1014-5.	1.3	0
223	Tracking immune cells during organ rejection. Liver Transplantation, 2006, 12, 1015-6.	1.3	0
224	Steroid use in liver transplantation: none, perioperative, or full course. Liver Transplantation, 2006, 12, 1294-5.	1.3	2
225	A new reason for intraoperative blood flow measurement: improving liver allograft function. Liver Transplantation, 2006, 12, 1295-6.	1.3	0
226	Another dendritic cell enters the transplant story. Liver Transplantation, 2006, 12, 1296-7.	1.3	0
227	A modified stenting procedure for bile duct reconstruction. Liver Transplantation, 2006, 12, 1431-2.	1.3	0
228	Another donor derived pathogen to watch out for. Liver Transplantation, 2006, 12, 1432-3.	1.3	0
229	Hepatic arterial vasospasm early after liver transplantation?. Liver Transplantation, 2006, 12, 1433-4.	1.3	0
230	Innate immunity involved in the pathogenesis of nonalcoholic steatohepatitis. Liver Transplantation, 2006, 12, 1553-4.	1.3	0
231	Using extended criteria donor (ECD) livers: three strikes and you're almost out. Liver Transplantation, 2006, 12, 1554-5.	1.3	0
232	Abdominal compartment syndrome: is the liver involved?. Liver Transplantation, 2006, 12, 1555-6.	1.3	0
233	CTLA4 Engagement is Required for Induction of Murine Liver Transplant Spontaneous Tolerance+. American Journal of Transplantation, 2005, 5, 978-986.	2.6	75
234	Using Root Cause Analysis to Improve Survival in a Liver Transplant Program1. Journal of Surgical Research, 2005, 129, 6-16.	0.8	23

#	ARTICLE	IF	CITATIONS
235	Role of the Liver in Peripheral Tolerance: Induction Through Oral Antigen Feeding. American Journal of Transplantation, 2004, 4, 1574-1582.	2.6	21
236	PROSPECTIVE, RANDOMIZED TRIAL OF THE EFFECT OF ANTIBODY INDUCTION IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION: THREE-YEAR RESULTS1. Transplantation, 2004, 77, 1269-1275.	0.5	70
237	Optimal grade transition and selection of closed-loop controllers in a gas-phase olefin polymerization fluidized bed reactor. Chemical Engineering Science, 2003, 58, 3643-3658.	1.9	106
238	Dynamics of Hepatitis C Virus Replication in Human Liver. American Journal of Pathology, 2003, 163, 433-444.	1.9	58
239	Optimal grade transition campaign scheduling in a gas-phase polyolefin FBR using mixed integer dynamic optimization. Computer Aided Chemical Engineering, 2003, 14, 71-76.	0.3	9
240	Robust model-based Controllers via Parametric Programming. Computer Aided Chemical Engineering, 2002, 10, 541-546.	0.3	5
241	An Industrial Case Study in Simultaneous Design and Control using Mixed-Integer Dynamic Optimization. Computer Aided Chemical Engineering, 2002, 10, 163-168.	0.3	3
242	Optimization-Based Methodologies for Integrating Design and Control in Cryogenic Plants. Computer Aided Chemical Engineering, 2002, 10, 331-336.	0.3	4
243	The explicit model-based control law for continuous time systems via parametric programming - INV5105. , 2002, , .		4
244	Optimal design and control of a high-purity industrial distillation system. Computers and Chemical Engineering, 2001, 25, 141-150.	2.0	25
245	Rescue of Acute Portal Vein Thrombosis After Liver Transplantation Using a Cavoportal Shunt at Re-transplantation. American Journal of Transplantation, 2001, 1, 284-287.	2.6	21
246	Simultaneous design and control optimisation under uncertainty. Computers and Chemical Engineering, 2000, 24, 261-266.	2.0	98
247	The interactions of design and control: double-effect distillation. Journal of Process Control, 2000, 10, 219-227.	1.7	48
248	Optimal design and control of an industrial distillation system. Computers and Chemical Engineering, 1999, 23, S875-S878.	2.0	16
249	Economic performance analysis in the design of on-line batch optimization systems. Journal of Process Control, 1999, 9, 61-78.	1.7	35
250	Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation. Tissue Antigens, 1998, 52, 435-443.	1.0	41
251	Economic analysis of different structures of on-line process optimization systems. Computers and Chemical Engineering, 1998, 22, 1257-1269.	2.0	32
252	Flexibility analysis and design of dynamic processes with stochastic parameters. Computers and Chemical Engineering, 1998, 22, S817-S820.	2.0	27

#	ARTICLE	IF	CITATIONS
253	End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. Journal of Hepatology, 1998, 29, 257-262.	1.8	92
254	RECOMBINANT HUMAN TUMOR NECROSIS FACTOR RECEPTOR Fc FUSION PROTEIN THERAPY IN KIDNEY TRANSPLANT RECIPIENTS UNDERGOING OKT3 INDUCTION THERAPY ^{1,2} . Transplantation, 1998, 66, 1732-1735.	0.5	6
255	Multigene Tracking of Hepatitis C Virus Quasispecies after Liver Transplantation: Correlation of Genetic Diversification in the Envelope Region with Asymptomatic or Mild Disease Patterns. Journal of Virology, 1998, 72, 10036-10043.	1.5	92
256	Performance analysis of on-line batch optimization systems. Computers and Chemical Engineering, 1997, 21, S867-S872.	2.0	9
257	RENAL DISEASE IN HEPATITIS C-POSITIVE LIVER TRANSPLANT RECIPIENTS. Transplantation, 1997, 63, 1287-1293.	0.5	52
258	The natural history of untreated focal allograft rejection in liver transplant recipients. Liver Transplantation, 1996, 2, 154-160.	1.9	18
259	Optimization as a tool for design/control integration. Computers and Chemical Engineering, 1996, 20, 315-323.	2.0	68
260	Switchability analysis. Computers and Chemical Engineering, 1996, 20, 469-474.	2.0	33
261	Computer generation of process models. Computers and Chemical Engineering, 1996, 20, 635-639.	2.0	24
262	Economic analysis of different structures of on-line process optimization systems. Computers and Chemical Engineering, 1996, 20, S551-S556.	2.0	12
263	Optimal synthesis and design of dynamic systems under uncertainty. Computers and Chemical Engineering, 1996, 20, S895-S900.	2.0	44
264	First-pass metabolism of midazolam by the human intestine*. Clinical Pharmacology and Therapeutics, 1996, 60, 14-24.	2.3	409
265	Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism*. Clinical Pharmacology and Therapeutics, 1996, 59, 491-502.	2.3	547
266	USE OF A WALLSTENT IN SUCCESSFUL TREATMENT OF IVC OBSTRUCTION FOLLOWING LIVER TRANSPLANTATION. Transplantation, 1996, 61, 669-672.	0.5	40
267	Hepatitis c-associated glomerular disease in liver transplant recipients. Liver Transplantation, 1995, 1, 166-175.	1.9	29
268	Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features. Hepatology, 1995, 22, 1-9.	3.6	169
269	Use of Ultrasound and Cystoscopically Guided Pancreatic Allograft Biopsies and Transabdominal Renal Allograft Biopsies: Safety and Efficacy in Kidney-Pancreas Transplant Recipients. Journal of Urology, 1995, 153, 316-321.	0.2	40
270	Optimizing control of a refinery gas-tail. Computers and Chemical Engineering, 1993, 17, 301-308.	2.0	1

#	ARTICLE	IF	CITATIONS
271	Robust parameter estimation in on-line optimizationâ€™part 2. Application to an industrial process. Computers and Chemical Engineering, 1993, 17, 663-669.	2.0	10
272	Experimental use of high-frequency ultrasound to image bowel wall after porcine intestinal transplantation. Journal of Pediatric Surgery, 1993, 28, 591-596.	0.8	2
273	IMMUNOSUPPRESSIVE THERAPY AS A DETERMINANT OF TRANSPLANTATION OUTCOMES. Transplantation, 1993, 55, 1297-1305.	0.5	23
274	Cyclic interdigestive pancreatic exocrine secretion: Is it mediated by neural or hormonal mechanisms?. Gastroenterology, 1992, 102, 1378-1384.	0.6	32
275	REVERSIBLE CYCLOSPORINE ARTERIOLOPATHY. Transplantation, 1992, 54, 732-733.	0.5	22
276	Robust parameter estimation in on-line optimizationâ€™part I. methodology and simulated case study. Computers and Chemical Engineering, 1992, 16, 545-562.	2.0	37
277	Cyclic interdigestive pancreatic exocrine secretion: Is it mediated by neural or hormonal mechanisms?. Gastroenterology, 1992, 102, 1378-1384.	0.6	1
278	THE EFFECT OF SOMATOSTATIN 201â€™995 ON THE EARLY COURSE OF PORCINE PANCREATODUODENAL ALLOTRANSPLANTATION. Transplantation, 1991, 51, 31-36.	0.5	9
279	DIFFERENTIAL DIAGNOSIS OF HYPOAMYLASURIA IN PANCREAS ALLOGRAFT RECIPIENTS WITH URINARY EXOCRINE DRAINAGE. Transplantation, 1990, 49, 359-362.	0.5	34
280	EVIDENCE THAT THE SOLUBLE INTERLEUKIN 2 RECEPTOR LEVEL MAY DETERMINE THE OPTIMAL TIME FOR CYSTOSCOPICALLY-DIRECTED BIOPSY IN PANCREATODUODENAL ALLOGRAFT RECIPIENTS. Transplantation, 1990, 49, 363-366.	0.5	18
281	Histologic Diagnosis of Rejection by Using. American Journal of Surgical Pathology, 1990, 14, 837-846.	2.1	32
282	Pancreas Transplantation at Mayo: I. Patient Selection. Mayo Clinic Proceedings, 1990, 65, 475-482.	1.4	7
283	Pancreas Transplantation at Mayo: III. Multidisciplinary Management. Mayo Clinic Proceedings, 1990, 65, 496-508.	1.4	17
284	Pancreas Transplantation at Mayo: II. Operative and Perioperative Management. Mayo Clinic Proceedings, 1990, 65, 483-495.	1.4	11
285	Persistent centrilobular necroses in hepatic allografts. Human Pathology, 1990, 21, 656-661.	1.1	57
286	Choosing Control Structures for Continuous Processes based on Economics. , 1990, , .		0
287	Acute Hepatic Failure: The Emerging Role of Orthotopic Liver Transplantation. Mayo Clinic Proceedings, 1989, 64, 424-428.	1.4	57
288	Endotheliitis in Hepatic Allografts. Mayo Clinic Proceedings, 1989, 64, 545-554.	1.4	23

#	ARTICLE	IF	CITATIONS
289	Diversion of the gastroduodenal vein: an in situ model of systemic insulin drainage. Diabetes Research and Clinical Practice, 1989, 7, 109-114.	1.1	2
290	Failure of Interferon To Prevent Recurrent Hepatitis B Infection in Hepatic Allograft. Mayo Clinic Proceedings, 1989, 64, 429-432.	1.4	48
291	Immunohistologic Pattern of the Portal T-Lymphocyte Infiltration in Hepatic Allograft Rejection. Mayo Clinic Proceedings, 1989, 64, 565-569.	1.4	12
292	Plasma Glucose Concentrations During Liver Transplantation. Mayo Clinic Proceedings, 1989, 64, 241-245.	1.4	31
293	Identifying and solving problems in engineering design. Studies in Higher Education, 1989, 14, 169-181.	2.9	18
294	SEQUENTIAL HISTOPATHOLOGIC CHANGES IN PANCREATOCODUODENAL ALLOGRAFT REJECTION IN DOGS. Transplantation, 1989, 48, 764-768.	0.5	8
295	SOLUBLE INTERLEUKIN-2 RECEPTOR LEVEL AS AN INDICATOR OF LIVER ALLOGRAFT REJECTION. Transplantation, 1989, 47, 77-81.	0.5	61
296	EOSINOPHIL GRANULE MAJOR BASIC PROTEIN IN ACUTE RENAL ALLOGRAFT REJECTION. Transplantation, 1989, 47, 959-963.	0.5	38
297	An implementation of quasi-newton methods for solving sets of nonlinear equations. Computers and Chemical Engineering, 1988, 12, 767-776.	2.0	11
298	Sparse newton-like methods in equation oriented flowsheeting. Computers and Chemical Engineering, 1988, 12, 791-805.	2.0	8
299	Scale invariant quasi-Newton methods for the solution of nonlinear equations. Computers and Chemical Engineering, 1988, 12, 91-97.	2.0	8
300	Canine Pancreaticoduodenal Allotransplantation: A Preparation for Human Pancreatic Transplantation. Journal of Investigative Surgery, 1988, 1, 97-106.	0.6	2
301	INFLUENCE OF POSITIVE LYMPHOCYTE CROSSMATCH AND HLA MISMATCHING ON VANISHING BILE DUCT SYNDROME IN HUMAN LIVER ALLOGRAFTS. Transplantation, 1988, 45, 376-379.	0.5	107
302	SPLENIC ARTERY ANEURYSMS IN LIVER TRANSPLANT PATIENTS. Transplantation, 1988, 45, 386-388.	0.5	89
303	SELECTIVE BOWEL DECONTAMINATION TO DECREASE GRAM-NEGATIVE AEROBIC BACTERIAL AND CANDIDA COLONIZATION AND PREVENT INFECTION AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1988, 45, 570-574.	0.5	139
304	IMMUNOHISTOLOGIC LABELING AS AN INDICATOR OF LIVER ALLOGRAFT REJECTION. Transplantation, 1987, 43, 105-107.	0.5	23
305	The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology, 1987, 7, 476-483.	3.6	200
306	The updating of LU factors in quasi-Newton methods. Computers and Chemical Engineering, 1986, 10, 241-247.	2.0	4

#	ARTICLE	IF	CITATIONS
307	Efficient solution of design problems using a sequential-modular flowsheeting programme. Computers and Chemical Engineering, 1979, 3, 375-381.	2.0	14
308	The explicit control law for hybrid systems via parametric programming. , 0, , .		16
309	Design of robust model-based tracking controllers via parametric programming. , 0, , .		3